A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

1998-2018

ABSTRACT

RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Combination chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This randomized trial is studying the side effects and best dose of topotecan when given together with high-dose cyclophosphamide, and carboplatin followed by an autologous peripheral blood stem cell transplant in treating patients with recurrent ovarian cancer or primary peritoneal cancer. Detailed Description OBJECTIVES: - To determine the maximum tolerated dose of topotecan hydrochloride combined with high-dose cyclophosphamide and carboplatin in the setting of autologous peripheral blood stem cell transplantation for relapsed, recurrent, or persistent ovarian epithelial or primary peritoneal cavity cancer. - To assess the toxicity of this regimen. OUTLINE: This is a dose escalation study of topotecan. - Autologous hematopoietic stem cell collection: Patients receive filgrastim subcutaneously (SC) daily for 5 days. Patients undergo leukapheresis per standard practice until a minimum of 2 x10^6 CD34+ cells/kg are collected and cryopreserved. - High-dose chemotherapy: Patients receive topotecan hydrochloride IV, cyclophosphamide IV, and carboplatin IV over 8 hours on days -6 to -3. - Autologous peripheral stem cell reinfusion: Patients undergo autologous peripheral blood stem cell transplantation on day 0. Patients also receive sargramostim SC daily beginning on day 5 and continuing until blood counts recover. After completion of study therapy, patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 5 years. More... »

URL

https://clinicaltrials.gov/show/NCT00652691

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Combination chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This randomized trial is studying the side effects and best dose of topotecan when given together with high-dose cyclophosphamide, and carboplatin followed by an autologous peripheral blood stem cell transplant in treating patients with recurrent ovarian cancer or primary peritoneal cancer.\n\nDetailed Description\nOBJECTIVES: - To determine the maximum tolerated dose of topotecan hydrochloride combined with high-dose cyclophosphamide and carboplatin in the setting of autologous peripheral blood stem cell transplantation for relapsed, recurrent, or persistent ovarian epithelial or primary peritoneal cavity cancer. - To assess the toxicity of this regimen. OUTLINE: This is a dose escalation study of topotecan. - Autologous hematopoietic stem cell collection: Patients receive filgrastim subcutaneously (SC) daily for 5 days. Patients undergo leukapheresis per standard practice until a minimum of 2 x10^6 CD34+ cells/kg are collected and cryopreserved. - High-dose chemotherapy: Patients receive topotecan hydrochloride IV, cyclophosphamide IV, and carboplatin IV over 8 hours on days -6 to -3. - Autologous peripheral stem cell reinfusion: Patients undergo autologous peripheral blood stem cell transplantation on day 0. Patients also receive sargramostim SC daily beginning on day 5 and continuing until blood counts recover. After completion of study therapy, patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 5 years.", 
    "endDate": "2018-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00652691", 
    "keywords": [
      "topotecan", 
      "high dose", 
      "peripheral blood stem cell", 
      "rationale", 
      "Colony-Stimulating Factor", 
      "Granulocyte Colony-Stimulating Factor", 
      "stem cell", 
      "patient", 
      "bone marrow", 
      "blood", 
      "Combination Drug Therapy", 
      "stem cell transplant", 
      "blood-forming cell", 
      "Drug Therapy", 
      "randomized trial", 
      "side effect", 
      "dose", 
      "carboplatin", 
      "recurrent ovarian cancer", 
      "maximum tolerated dose", 
      "setting", 
      "peritoneal cavity", 
      "toxicity", 
      "regimen", 
      "outline", 
      "dose escalation study", 
      "hematopoietic stem cell", 
      "SC", 
      "leukapheresis", 
      "standard practice", 
      "high-dose chemotherapy", 
      "cyclophosphamide", 
      "blood count", 
      "completion", 
      "therapy"
    ], 
    "name": "A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00652691"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00005.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }
    ], 
    "startDate": "1998-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/bmt.2009.181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034641898", 
          "https://doi.org/10.1038/bmt.2009.181"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00652691"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00652691'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00652691'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00652691'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00652691'


 

This table displays all metadata directly associated to this object as RDF triples.

61 TRIPLES      16 PREDICATES      52 URIs      44 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00652691 schema:about anzsrc-for:3048
2 anzsrc-for:3142
3 schema:description RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Combination chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This randomized trial is studying the side effects and best dose of topotecan when given together with high-dose cyclophosphamide, and carboplatin followed by an autologous peripheral blood stem cell transplant in treating patients with recurrent ovarian cancer or primary peritoneal cancer. Detailed Description OBJECTIVES: - To determine the maximum tolerated dose of topotecan hydrochloride combined with high-dose cyclophosphamide and carboplatin in the setting of autologous peripheral blood stem cell transplantation for relapsed, recurrent, or persistent ovarian epithelial or primary peritoneal cavity cancer. - To assess the toxicity of this regimen. OUTLINE: This is a dose escalation study of topotecan. - Autologous hematopoietic stem cell collection: Patients receive filgrastim subcutaneously (SC) daily for 5 days. Patients undergo leukapheresis per standard practice until a minimum of 2 x10^6 CD34+ cells/kg are collected and cryopreserved. - High-dose chemotherapy: Patients receive topotecan hydrochloride IV, cyclophosphamide IV, and carboplatin IV over 8 hours on days -6 to -3. - Autologous peripheral stem cell reinfusion: Patients undergo autologous peripheral blood stem cell transplantation on day 0. Patients also receive sargramostim SC daily beginning on day 5 and continuing until blood counts recover. After completion of study therapy, patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 5 years.
4 schema:endDate 2018-12-01T00:00:00Z
5 schema:keywords Colony-Stimulating Factor
6 Combination Drug Therapy
7 Drug Therapy
8 Granulocyte Colony-Stimulating Factor
9 SC
10 blood
11 blood count
12 blood-forming cell
13 bone marrow
14 carboplatin
15 completion
16 cyclophosphamide
17 dose
18 dose escalation study
19 hematopoietic stem cell
20 high dose
21 high-dose chemotherapy
22 leukapheresis
23 maximum tolerated dose
24 outline
25 patient
26 peripheral blood stem cell
27 peritoneal cavity
28 randomized trial
29 rationale
30 recurrent ovarian cancer
31 regimen
32 setting
33 side effect
34 standard practice
35 stem cell
36 stem cell transplant
37 therapy
38 topotecan
39 toxicity
40 schema:name A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer
41 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00652691
42 schema:sdDatePublished 2019-03-07T15:23
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N96bf547431044d33870f013e920db81d
45 schema:sponsor https://www.grid.ac/institutes/grid.48336.3a
46 schema:startDate 1998-08-01T00:00:00Z
47 schema:subjectOf sg:pub.10.1038/bmt.2009.181
48 schema:url https://clinicaltrials.gov/show/NCT00652691
49 sgo:license sg:explorer/license/
50 sgo:sdDataset clinical_trials
51 rdf:type schema:MedicalStudy
52 N96bf547431044d33870f013e920db81d schema:name Springer Nature - SN SciGraph project
53 rdf:type schema:Organization
54 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
55 rdf:type schema:DefinedTerm
56 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
57 rdf:type schema:DefinedTerm
58 sg:pub.10.1038/bmt.2009.181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034641898
59 https://doi.org/10.1038/bmt.2009.181
60 rdf:type schema:CreativeWork
61 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...